Morepen Laboratories has completed the first phase of its manufacturing capacity expansion program ahead of schedule. The company informed stock exchanges about the development on 7 September 2026.
The disclosure is classified as a business update on manufacturing capacity. It relates to the company’s installed reactor capacity for API and CDMO operations.
Capacity Moves To 614 KL
Under the first phase, installed reactor capacity has increased from 535 KL to 614 KL. The addition in this phase is 79 KL.
Reactor capacity is used to measure available volume for chemical synthesis in pharmaceutical manufacturing. In API production, reactors are used for carrying out reactions that form the active ingredient. The installed capacity figure indicates total volume available across reactors at the facility.
The company stated that the first phase has been completed ahead of the previously indicated timeline. The intimation does not specify the original timeline or the start date of the expansion work.
What API And CDMO Operations Cover
API stands for Active Pharmaceutical Ingredient. It is the substance that produces the intended therapeutic effect in a finished formulation. API manufacturing involves multiple chemical steps conducted in reactors and other equipment.
CDMO stands for Contract Development and Manufacturing Organization. In this model, a company undertakes development and manufacturing activities for other pharmaceutical companies. The work can include process development, scale up and commercial manufacturing.
Morepen Laboratories operates in both API and CDMO segments. The company said the expanded capacity is for these two business lines.
Manufacturing Readiness For Commercial Supplies
According to the filing, the capacity enhancement strengthens manufacturing readiness for the ongoing scale up of commercial CDMO supplies.
Scale up of commercial supplies refers to the transition from smaller batches to larger commercial volumes for customers. Manufacturing readiness involves having sufficient reactor volume, supporting utilities and operational capability to handle increased volumes.
The company also said the enhanced capacity will support its existing API business. Existing API business covers ongoing production of active ingredients that the company already manufactures and supplies.
Support For Future Customer Programs
The filing states that the capacity will support future customer programs. Customer programs in a CDMO context generally refer to projects being undertaken for clients, including new molecules or existing molecules being transferred for manufacturing.
Future programs are typically developed over a period that includes technology transfer, process validation and regulatory documentation. Availability of reactor capacity is one of the prerequisites for taking up such programs.
Morepen said the first phase expansion will help in handling these programs along with its current commercial work.
Platform Strategy Mentioned By Company
The company described the completion as an important milestone in its strategy to build a larger, scalable and globally compliant manufacturing platform.
A larger platform refers to increased installed capacity across manufacturing units. A scalable platform refers to infrastructure that can be expanded further as demand increases. A globally compliant platform refers to facilities that meet standards required for supplying to regulated markets.
Morepen said the strategy is focused on long duration customer partnerships. Long duration partnerships in the CDMO business refer to multi year supply arrangements with customers.
The company also said the strategy is focused on sustained growth across API and CDMO businesses. Sustained growth refers to continued expansion of operations across these segments.
Nature Of The Intimation
The letter is dated 7 September 2026 and was submitted as a business update. The company said the update is for information and record of exchanges.
The disclosure provides the capacity figures before and after the first phase. It mentions the business areas that will be supported by the enhanced capacity.
The filing does not provide details on capital expenditure for the phase, equipment added, or schedule for subsequent phases. It also does not provide production volume guidance or customer names.
Summary Of Update
| Item | Detail |
|---|---|
| Company | Morepen Laboratories Limited |
| Date Of Update | 7 September 2026 |
| Phase | First phase of manufacturing capacity expansion completed ahead of schedule |
| Capacity Before | 535 KL |
| Capacity After | 614 KL |
| Incremental Addition | 79 KL |
| Areas Supported | Ongoing scale up of commercial CDMO supplies, existing API business, future customer programs |